• Hupaderm

    Development of a HuPaDerm Product Portfolio is targeting the treatment of the leading cause of cervical cancer as well as papillomatosis, genital warts and, later cancer, caused by different varieties of the Human papillomavirus ("HPV"). More than 30 to 40 types of HPV are typically transmitted through sexual contact.

    Currently two different prophylactic vaccines are available for the prevention of HPV, Gardasil and Cervarix. These help people reduce the risk of infection. However there are no therapeutic vaccines for those who are already infected.

    Health experts estimate that there are more cases of genital HPV infection than any other sexually transmitted disease (STD) in the United States. According to the American Social Health Association, approximately 5.5 million new cases of sexually transmitted HPV infections are reported every year, though 6.2 million new infections are estimated to occur. At least 20 million people in the United States are already infected -- most of them may not even know it.

    HupaDerm is being developed for those already infected.